The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...
"KEYLYNK-001 is the first positive phase 3 trial for Keytruda plus Lynparza, highlighting our commitment to research that may ...
The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t gotten worse after getting platinum-based chemo and radiation at the same ...
AstraZeneca AZN announced that the FDA has accepted and granted priority review to its supplemental biologics license application (sBLA) seeking expanded use of its blockbuster drug, Imfinzi ...
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...
A treatment for a rare type of cancer has been accepted for use on the NHS in Scotland. The Scottish Medicines Consortium ...
The US Food and Drug Administration (FDA) has granted priority review to AstraZeneca's supplemental biologics licence ...
If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of ...
AstraZeneca (AZN) said the FDA has accepted its supplemental Biologics License Application for Imfinzi for Priority Review for the treatment of muscle-invasive bladder cancer.
The FDA has approved Imfinzi (durvalumab) to treat LS-SCLC that has not progressed after concurrent platinum-based chemotherapy and radiation.
6d
AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression ...
AstraZeneca’s (AZN) supplemental biologics license application, or sBLA, for Imfinzi has been accepted and granted priority review in the U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback